PMID- 23918069
OWN - NLM
STAT- MEDLINE
DCOM- 20140506
LR  - 20231106
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 18
IP  - 8
DP  - 2013
TI  - Overview and management of cardiac adverse events associated with tyrosine kinase 
      inhibitors.
PG  - 900-8
LID - 10.1634/theoncologist.2012-0466 [doi]
AB  - BACKGROUND: Small-molecule tyrosine kinase inhibitors (TKIs) may provide an 
      effective therapeutic option in patients with hematologic malignancies and solid 
      tumors. However, cardiovascular (CV) events, including hypertension, heart 
      failure, left ventricular systolic dysfunction, and QT prolongation, have emerged 
      as potential adverse events (AEs) with TKI therapy. PURPOSE: We review what is 
      known about the mechanism of action of CV AEs associated with TKI use and discuss 
      therapeutic interventions that may prevent and manage these events in clinical 
      practice. METHODS: References for this review were identified through searches of 
      PubMed and Medline databases, and only papers published in English were 
      considered. Search terms included "cardiac," "cardiovascular," "cancer," and 
      "kinase inhibitor." Related links in the databases were reviewed, along with 
      relevant published guidelines. RESULTS: Although the link between rising blood 
      pressure (BP) and CV AEs is observed but not proven, good clinical practice 
      supports an aggressive policy on proper long-term BP management. There are 
      insufficient data from randomized controlled clinical trials to show indisputably 
      that aggressive or effective heart failure therapy in patients receiving TKIs 
      will fundamentally change outcomes; however, clinical practice suggests that this 
      is an effective long-term approach. Recognizing that QT prolongation is 
      associated with TKI use facilitates identification of patients at high risk for 
      this CV AE and increases awareness of the need for routine electrocardiograms and 
      electrolyte monitoring for those receiving TKI treatment. CONCLUSION: Regular 
      monitoring, early recognition, and appropriate interventions for CV AEs can help 
      more patients derive the benefit of long-term TKI therapy.
FAU - Lenihan, Daniel J
AU  - Lenihan DJ
AD  - Vanderbilt Heart and Vascular Institute, Nashville, Tennessee 37232-8802, USA. 
      daniel.lenihan@Vanderbilt.Edu
FAU - Kowey, Peter R
AU  - Kowey PR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130805
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
CIN - Oncologist. 2014 Mar;19(3):306-7. PMID: 24643716
CIN - Oncologist. 2014 Mar;19(3):307. PMID: 24643717
MH  - Cardiovascular Diseases/chemically induced/*pathology/therapy
MH  - Drug-Related Side Effects and Adverse Reactions/classification/pathology/*therapy
MH  - Heart Failure/chemically induced/pathology/therapy
MH  - Humans
MH  - Hypertension/chemically induced/pathology/therapy
MH  - Neoplasms/*drug therapy/pathology
MH  - Protein Kinase Inhibitors/*adverse effects/classification/therapeutic use
MH  - Ventricular Dysfunction, Left/chemically induced/pathology/therapy
PMC - PMC3755926
OTO - NOTNLM
OT  - Adverse events
OT  - Cancer
OT  - Cardiac
OT  - Cardiovascular
OT  - TKIs
OT  - Tyrosine kinase inhibitors
COIS- Disclosures of potential conflicts of interest may be found at the end of this 
      article.
EDAT- 2013/08/07 06:00
MHDA- 2014/05/07 06:00
PMCR- 2014/08/01
CRDT- 2013/08/07 06:00
PHST- 2013/08/07 06:00 [entrez]
PHST- 2013/08/07 06:00 [pubmed]
PHST- 2014/05/07 06:00 [medline]
PHST- 2014/08/01 00:00 [pmc-release]
AID - theoncologist.2012-0466 [pii]
AID - 3843615 [pii]
AID - 10.1634/theoncologist.2012-0466 [doi]
PST - ppublish
SO  - Oncologist. 2013;18(8):900-8. doi: 10.1634/theoncologist.2012-0466. Epub 2013 Aug 
      5.